Younis T - Search Results

1

The clinical utility of baseline cardiac assessments prior to adjuvant anthracycline chemotherapy in breast cancer: a systematic review and meta-analysis.

O'Brien P, Matheson K, Jeyakumar A, Anderson K, Younis T. O'Brien P, et al. Among authors: younis t. Breast Cancer Res Treat. 2019 Apr;174(2):357-363. doi: 10.1007/s10549-018-05114-7. Epub 2019 Jan 2. Breast Cancer Res Treat. 2019. PMID: 30603999

2

Cost-utility of adjuvant hormone therapies for breast cancer in post-menopausal women: sequential tamoxifen-exemestane and upfront anastrozole.

Skedgel C, Rayson D, Dewar R, Younis T. Skedgel C, et al. Among authors: younis t. Breast Cancer Res Treat. 2007 Mar;101(3):325-33. doi: 10.1007/s10549-006-9299-4. Epub 2006 Aug 2. Breast Cancer Res Treat. 2007. PMID: 16897433

3

Wait times for breast cancer care.

Saint-Jacques N, Younis T, Dewar R, Rayson D. Saint-Jacques N, et al. Among authors: younis t. Br J Cancer. 2007 Jan 15;96(1):162-8. doi: 10.1038/sj.bjc.6603523. Epub 2006 Dec 19. Br J Cancer. 2007. PMID: 17179986 Free PMC article.

4

Cost-utility of adjuvant hormone therapies with aromatase inhibitors in post-menopausal women with breast cancer: upfront anastrozole, sequential tamoxifen-exemestane and extended tamoxifen-letrozole.

Skedgel C, Rayson D, Dewar R, Younis T. Skedgel C, et al. Among authors: younis t. Breast. 2007 Jun;16(3):252-61. doi: 10.1016/j.breast.2006.12.002. Epub 2007 Jan 4. Breast. 2007. PMID: 17207623

5

Clinical and pathological correlations in male breast cancer: intratumoral aromatase expression via tissue microarray.

Dakin Haché K, Gray S, Barnes PJ, Dewar R, Younis T, Rayson D. Dakin Haché K, et al. Among authors: younis t. Breast Cancer Res Treat. 2007 Oct;105(2):169-75. doi: 10.1007/s10549-006-9448-9. Epub 2007 Feb 1. Breast Cancer Res Treat. 2007. PMID: 17268818

6

Adjuvant chemotherapy for breast cancer: a cost-utility analysis of FEC-D vs. FEC 100.

Younis T, Rayson D, Sellon M, Skedgel C. Younis T, et al. Breast Cancer Res Treat. 2008 Sep;111(2):261-7. doi: 10.1007/s10549-007-9770-x. Epub 2007 Oct 5. Breast Cancer Res Treat. 2008. PMID: 17914669

7

Cost-effectiveness analysis of adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-positive breast cancer: modeling the downstream effects.

Au HJ, Golmohammadi K, Younis T, Verma S, Chia S, Fassbender K, Jacobs P. Au HJ, et al. Among authors: younis t. Breast Cancer Res Treat. 2009 Apr;114(3):579-87. doi: 10.1007/s10549-008-0034-1. Epub 2008 Apr 29. Breast Cancer Res Treat. 2009. PMID: 18443903

8

Adjuvant chemotherapy uptake in non-small cell lung cancer.

Younis T, Al-Fayea T, Virik K, Morzycki W, Saint-Jacques N. Younis T, et al. J Thorac Oncol. 2008 Nov;3(11):1272-8. doi: 10.1097/JTO.0b013e318189f562. J Thorac Oncol. 2008. PMID: 18978562 Free article.

9

The cost-utility of sequential adjuvant trastuzumab in women with Her2/Neu-positive breast cancer: an analysis based on updated results from the HERA Trial.

Skedgel C, Rayson D, Younis T. Skedgel C, et al. Among authors: younis t. Value Health. 2009 Jul-Aug;12(5):641-8. doi: 10.1111/j.1524-4733.2009.00511.x. Value Health. 2009. PMID: 19490562 Free article. Clinical Trial.

10

Comparison of clinical-pathologic characteristics and outcomes of true interval and screen-detected invasive breast cancer among participants of a Canadian breast screening program: a nested case-control study.

Rayson D, Payne JI, Abdolell M, Barnes PJ, MacIntosh RF, Foley T, Younis T, Burns A, Caines J. Rayson D, et al. Among authors: younis t. Clin Breast Cancer. 2011 Mar;11(1):27-32. doi: 10.3816/CBC.2011.n.005. Clin Breast Cancer. 2011. PMID: 21421519

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

121 results

Search Page

Filters